HCA Healthcare, Inc. (HCA)
Health Care · Health Care Facilities · US stock · S&P 500 component
$458.84
▼ -9.66 (2.06%)
Fair valueUndervalued
$996 +117.0% to fair value
$498fair band $697–$1,295$1,494
Day's range
$453.94 – $472.49
52-week range
$353.34 – $553.56
Red flags⚠ Negative equity
About HCA Healthcare, Inc.
HCA Healthcare operates one of the largest networks of hospitals and outpatient facilities in the United States, with a presence in the United Kingdom as well. Its facilities include acute care hospitals, emergency rooms, surgery centers and urgent care clinics. Revenue comes from patient services paid by government programs such as Medicare and Medicaid, by commercial insurers and by individuals, so reimbursement rates and patient volumes strongly influence results.
The figures show revenue of $76.4 billion for the last twelve months and three-year growth of 7.9% a year. It reports an operating margin of 15.8%. Capital is used to generate a return on invested capital of 24%. Leverage, measured as net debt to EBITDA, is 3.0 times. The company pays a dividend with a yield of 0.7%. The site's X-Ray Score for the company is 63 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $353.34 – $553.56Volume 1,725,700Daily, split-adjusted
Vitals
Market cap$104.0B
52-week range$353.34 – $553.56
Volume (last day)1,725,700
P/E (TTM)15.9
EBIT / EV yield7.8%
Free-cash-flow yield7.6%
Dividend yield0.7%
Revenue (TTM)$76.4B
Net income (TTM)$6.8B
Operating margin15.8%
Return on capital23.6%
Debt incl. leases$48.0B
Cash & securities$940M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$996model spread $906 – $1,097
Undervalued
+117.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $459
Undervalued < $697Fair $697 – $1,295Overvalued > $1,295
10-year DCF (market-scaled)
$1,197
Peer multiples
$812
Earnings power floor (not blended)
$387
Fundamentals-adjusted multiple
$979
Growth the price implies
-0.2%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business at a low price
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
88/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield7.8%
Free-cash-flow yield7.6%
Fair value vs price2.2×
Growth
Fair
66/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)7.9%
EPS growth (3y)13.9%
Growth consistency100%
Profitability
Strong
72/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital23.6%
Operating margin15.8%
Financial health
Weak
34/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA3.0×
Interest cover5.3×
Dividends
Weak
45/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.7%
Dividends vs free cash flow9%
Dividend growth1.3%
Quarterly results: last 6 quarters
+5.7%
Dec '24
+5.7%
Mar '25
+6.4%
Jun '25
+9.6%
Sep '25
+6.7%
Dec '25
+4.3%
Mar '26
Revenue against the same quarter a year earlier. Latest quarter revenue $19.1B, diluted EPS $7.15.
Compare with peers
UHS Universal Health Servi...66Other Health Care Facilities companies by X-Ray Score.
Fundamentals checklist
● 8 Good · ● 4 Average · ● 3 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldGood
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverBad
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 65/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $58.8B | $60.2B | $65.0B | $70.6B | $75.6B |
| Operating income | $11.4B | $10.3B | $9.6B | $10.6B | $12.1B |
| Net income | $7.0B | $5.6B | $5.2B | $5.8B | $6.8B |
| Operating cash flow | $9.0B | $8.5B | $9.4B | $10.5B | $12.6B |
| Operating margin | 19.4% | 17.1% | 14.8% | 15.0% | 16.0% |
| Free cash flow | $5.4B | $4.1B | $4.7B | $5.6B | $7.7B |
| Diluted EPS | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 452.0 | Bullish |
| EMA 10 | 453.9 | Bullish |
| SMA 20 | 441.0 | Bullish |
| EMA 20 | 444.3 | Bullish |
| SMA 50 | 426.1 | Bullish |
| EMA 50 | 429.6 | Bullish |
| SMA 100 | 406.6 | Bullish |
| EMA 100 | 425.0 | Bullish |
| SMA 200 | 443.5 | Bullish |
| EMA 200 | 426.8 | Bullish |
Oscillators (daily)
| RSI (14) | 63.14 | Neutral |
| MACD (12, 26) | 11.36 | Bullish |
| Momentum (12) | 7.52 | Bullish |
| Stochastic %K (14) | 64.51 | Neutral |
| Williams %R (14) | -35.49 | Neutral |
| CCI (20) | 116.7 | Bearish |
Pivot points (classic, last session)
S3 432.5 | S2 443.2 | S1 451.0 | Pivot 461.8 | R1 469.6 | R2 480.3 | R3 488.1 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
3.06 USD
Yield on today's price
0.67%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 16 Sep 2026 | 0.7800 |
| 16 Jun 2026 | 0.7800 |
| 17 Mar 2026 | 0.7800 |
| 15 Dec 2025 | 0.7200 |
| 16 Sep 2025 | 0.7200 |
| 16 Jun 2025 | 0.7200 |
| 17 Mar 2025 | 0.7200 |
| 13 Dec 2024 | 0.6600 |
| 16 Sep 2024 | 0.6600 |
| 14 Jun 2024 | 0.6600 |
| 14 Mar 2024 | 0.6600 |
| 13 Dec 2023 | 0.6000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
HCA SEC filings
29 Jul 2026
8-KSEC EDGAR
Other events
28 Jul 2026
10-QSEC EDGAR
Quarterly report
24 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
14 Jul 2026
8-KSEC EDGAR
Results of operations; Regulation FD disclosure
18 Jun 2026
8-KSEC EDGAR
Director or officer change
30 Apr 2026
8-KSEC EDGAR
Entered a material agreement; Other events
29 Apr 2026
424B5SEC EDGAR
424B5
29 Apr 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.